Addressing the
#1 Cause of Death After a Heart Attack

We’re Reinventing the Standard of Care in Mechanical Circulatory Support

THE PROBLEM

A serious, life-threatening condition—Cardiogenic Shock

There remains a significant unmet clinical need

#1 cause of death after a heart attack

Key risk for patients with Acute Decompensated Heart Failure

Cardiogenic shock has 40%-60% mortality rate

Mechanical circulatory support (MCS) is required when the heart is unable to pump sufficient blood & oxygen to the body, resulting in end-organ failure

Significant complication risks with the current standard of care

Major bleeding

Sepsis

Infection

Vascular injury

Hemolysis

Arterial blockages leading to limb ischemia or stroke

OUR SOLUTION

Introducing Percutaneous Synchronized Cardiac Assist (PSCA)

Our implant uses an inflatable balloon to apply ECG-synchronized left ventricular compression, without entering the heart or bloodstream

How it works

Highly differentiated technology

This novel implant and its extravascular placement (using a simple, less invasive procedure) is designed to avoid many of the risks and complications of current, temporary MCS devices

Extravascular/extracardiac

Less invasive and avoids hemolysis, stroke

No contrast imaging

Reduces contrast-induced nephropathy

No anticoagulants

Minimizes bleeding

THE OPPORTUNITY

Platform play with multi-
billion $ global markets*

$18B

Acute Market | Cardiogenic Shock

$9B

Chronic Market | Heart Failure

Experienced Leadership Team

100+ years of combined experience successfully advancing innovation in leading MedTech companies

Gerardo Noriega

President/CEO
Albert Chin, MD

Chief Innovation Officer
Jim Heslin

IP Counsel
Susan Osborne

VP Regulatory, Clinical and Quality
Bezhad Behrooz

VP R&D and Operations
Ann Benham

Head of Marketing

World-Renowned Clinical Advisory Board

Daniel Burkhoff, MD, Ph.D

Director of Heart Failure,
Hemodynamics & MCS Cardiovascular
Research Foundation
Prof. Petr Neužil, MD

Chairman, Dept of Cardiology, Na Homolce Hospital, Prague, CZ
Mitchell Krukoff, MD

Director, Cardiovascular Devices Unit, Duke University Medical Center
Kendrick Shunk, MD

Chief Interventional Cardiology UCSF/SFVA
Dan Meyer, MD

Chief of Cardiac Transplantation,
Baylor Scott & White Hospital Dallas
William O'Neill, MD

Medical Director of the Center for Structural Heart Disease, Henry Ford Hospital
Henry Hsia, MD

Chief of VT and Electrophysiology at UCSF, FACC,
Professor of Medicine

Addressing the#1 Cause of Death After a Heart Attack

We’re Reinventing the Standard of Care in Mechanical Circulatory Support

THE PROBLEM

A serious, life-threatening condition—Cardiogenic Shock

There remains a significant unmet clinical need

Cardiogenic shock has 40%-60% mortality rate

Significant complication risks with the current standard of care

Major bleeding

Sepsis

Infection

Vascular injury

Hemolysis

Arterial blockages leading to limb ischemia or stroke

OUR SOLUTION

Introducing Percutaneous Synchronized Cardiac Assist (PSCA)

Our implant uses an inflatable balloon to apply ECG-synchronized left ventricular compression, without entering the heart or bloodstream

How it works

Highly differentiated technology

This novel implant and its extravascular placement (using a simple, less invasive procedure) is designed to avoid many of the risks and complications of current, temporary MCS devices

Less invasive and avoids hemolysis, stroke

Reduces contrast-induced nephropathy

Minimizes bleeding

THE OPPORTUNITY

Platform play with multi-billion $ global markets*

$18B

Acute Market | Cardiogenic Shock

$9B

Chronic Market | Heart Failure

Gerardo Noriega

Albert Chin, MD

Jim Heslin

Susan Osborne

Bezhad Behrooz

Ann Benham

Daniel Burkhoff, MD, Ph.D

Prof. Petr Neužil, MD

Mitchell Krukoff, MD

Kendrick Shunk, MD

Dan Meyer, MD

William O'Neill, MD

Henry Hsia, MD

Addressing the
#1 Cause of Death After a Heart Attack

Platform play with multi-
billion $ global markets*